Cargando…

High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients

Survival of diffuse large B-cell lymphoma (DLBCL) patients has improved by inclusion of rituximab. Refractory/recurrent disease caused by treatment resistance is, however, a major problem. Determinants of rituximab sensitivity are not fully understood, but effect of rituximab are enhanced by antagon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laursen, Maria Bach, Reinholdt, Linn, Schönherz, Anna Amanda, Due, Hanne, Jespersen, Ditte Starberg, Grubach, Lykke, Ettrup, Marianne Schmidt, Røge, Rasmus, Falgreen, Steffen, Sørensen, Suzette, Bødker, Julie Støve, Schmitz, Alexander, Johnsen, Hans E., Bøgsted, Martin, Dybkær, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366826/ https://www.ncbi.nlm.nih.gov/pubmed/30774774 http://dx.doi.org/10.18632/oncotarget.26588

Ejemplares similares

The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
por: Reinholdt, Linn, et al.
Publicado: (2016)

Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis
por: Jespersen, Ditte Starberg, et al.
Publicado: (2019)

Molecular classification of tissue from a transformed non-Hogkin’s lymphoma case with unexpected long-time remission
por: Bødker, Julie Støve, et al.
Publicado: (2017)

Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor
por: Rodrigo-Domingo, Maria, et al.
Publicado: (2014)

Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition
por: Falgreen, Steffen, et al.
Publicado: (2014)

MicroRNAs in B-cells: from normal differentiation to treatment of malignancies
por: Marques, Sara Correia, et al.
Publicado: (2014)

MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index
por: Due, Hanne, et al.
Publicado: (2020)

miR-155 as a Biomarker in B-Cell Malignancies
por: Due, Hanne, et al.
Publicado: (2016)

Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact
por: Schönherz, Anna A., et al.
Publicado: (2020)

Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates
por: Bilgrau, Anders E., et al.
Publicado: (2016)

hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine
por: Falgreen, Steffen, et al.
Publicado: (2016)

A model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells
por: Kloster, Maria Bro, et al.
Publicado: (2012)

Long Noncoding RNA Expression during Human B-Cell Development
por: Petri, Andreas, et al.
Publicado: (2015)

Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models
por: Falgreen, Steffen, et al.
Publicado: (2015)

Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives
por: Vesteghem, Charles, et al.
Publicado: (2019)

Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark
por: Bødker, Julie S., et al.
Publicado: (2020)

Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa
por: Marcussen, Mette, et al.
Publicado: (2017)

Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma
por: Marcussen, Mette, et al.
Publicado: (2018)

A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma
por: Issa, Issa Ismail, et al.
Publicado: (2021)

Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man
por: Bergkvist, Kim Steve, et al.
Publicado: (2014)

Generation of a Predictive Melphalan Resistance Index by Drug Screen of B-Cell Cancer Cell Lines
por: Boegsted, Martin, et al.
Publicado: (2011)

Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow – A proof of concept study
por: Nørgaard, Caroline Holm, et al.
Publicado: (2018)

Proof of the Concept to Use a Malignant B Cell Line Drug Screen Strategy for Identification and Weight of Melphalan Resistance Genes in Multiple Myeloma
por: Bøgsted, Martin, et al.
Publicado: (2013)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
por: Wei, Xiaolei, et al.
Publicado: (2014)

Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
por: Li, Xueying, et al.
Publicado: (2019)

Anti-Apoptotic Effects of Lentiviral Vector Transduction Promote Increased Rituximab Tolerance in Cancerous B-Cells
por: Ranjbar, Benyamin, et al.
Publicado: (2016)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
por: Claustre, Gwladys, et al.
Publicado: (2022)

Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis
por: Hong, Junshik, et al.
Publicado: (2010)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma
por: Thomsen, Emil Aagaard, et al.
Publicado: (2020)

Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent
por: Sekiguchi, Naohiro, et al.
Publicado: (2018)

Rituximab-CHOP Induced Interstitial Pneumonitis in Patients with Disseminated Extranodal Marginal Zone B Cell Lymphoma
por: Kim, Kwang Min, et al.
Publicado: (2008)

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma
por: Lisenko, K., et al.
Publicado: (2017)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs
por: Nesic, Marijana, et al.
Publicado: (2021)

Optimization of Preanalytical Variables for cfDNA Processing and Detection of ctDNA in Archival Plasma Samples
por: Nesic, Marijana, et al.
Publicado: (2021)

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fl1ogm2uth18dddpgeme6qbidr